28593-25-1Relevant articles and documents
Preparation and application of triazole heterocyclic compound containing heteroaryl amide structure
-
Paragraph 0121; 0125; 0126, (2019/11/14)
The invention discloses a triazole heterocyclic compound containing a heteroaryl amide structure, a geometrical isomer of triazole heterocyclic compound containing the heteroaryl amide structure and pharmacologically acceptable salt, hydrate, solvate or p
Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against plasmodium falciparum dihydroorotate dehydrogenase
Marwaha, Alka,White, John,El-mazouni, Farah,Creason, Sharon A,Kokkonda, Sreekanth,Buckner, Frederick S.,Charman, Susan A.,Phillips, Margaret A.,Rathod, Pradipsinh K.
, p. 7425 - 7436 (2012/11/07)
Plasmodium falciparum causes approximately 1 million deaths annually. However, increasing resistance imposes a continuous threat to existing drug therapies. We previously reported a number of potent and selective triazolopyrimidine-based inhibitors of P.